Overview

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Treatments:
Olaparib
Temozolomide